Constella for Irritable bowel syndrome with constipation
Quick answer: Constella is used for Irritable bowel syndrome with constipation as part of a guanylate cyclase-c agonist treatment regimen. Linaclotide activates intestinal guanylate cyclase-C, increasing cGMP, chloride and bicarbonate secretion, accelerating transit and reducing visceral pain The specific dosing for Irritable bowel syndrome with constipation is determined by your prescriber based on individual factors.
Why is Constella used for Irritable bowel syndrome with constipation?
Constella belongs to the Guanylate cyclase-C agonist class. Linaclotide activates intestinal guanylate cyclase-C, increasing cGMP, chloride and bicarbonate secretion, accelerating transit and reducing visceral pain This action makes it useful for treating or managing Irritable bowel syndrome with constipation in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Constella is the right choice for a specific patient depends on the type and severity of Irritable bowel syndrome with constipation, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Irritable bowel syndrome with constipation
Common adult dosing range: 290 mcg orally once daily (IBS-C); 145 mcg for CIC. The actual dose for Irritable bowel syndrome with constipation depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Constella medicine page.
What to expect
Constella treatment for Irritable bowel syndrome with constipation typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Irritable bowel syndrome with constipation
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Constella is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Guanylate cyclase-C agonist for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Constella
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Constella full prescribing information · All Guanylate cyclase-C agonist alternatives
Frequently asked questions
How effective is Constella for Irritable bowel syndrome with constipation?
Effectiveness varies by individual response, dose, and severity. Constella is one of several treatment options for Irritable bowel syndrome with constipation, supported by clinical evidence within the guanylate cyclase-c agonist class. Discuss expected response with your prescriber.
How long do I need to take Constella for Irritable bowel syndrome with constipation?
Treatment duration depends on the nature of Irritable bowel syndrome with constipation — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Constella when used for Irritable bowel syndrome with constipation?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Constella for Irritable bowel syndrome with constipation?
Yes. Multiple medicines and non-drug options exist for Irritable bowel syndrome with constipation. Alternatives within the guanylate cyclase-c agonist class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.